Peter B. Corr
Managing General Partner
Auven Therapeutics
Biotechnology
Stephen Evans-Freke
Managing General Partner
Auven Therapeutics
Biotechnology
Investors by Firm
- 01 Ventures Investors
- 1/0 Capital, LLC Investors
- 10X Venture Partners Investors
- 11-11 Ventures Investors
- 1315 Capital Investors
- 137 Ventures Investors
- 14W Investors
- 15th Rock Ventures Investors
- 1776 Investors
- 1855 Capital Investors
- 1984 Ventures Investors
- 1st Source Capital Corporation Investors
- 20/20 HealthCare Partners LLC Investors
- 2020 Ventures Investors
- 21 Centrale Partners Investors
- 21 Concordia Investors
- 21 Investimenti Investors
- 212 Ltd. Investors
- 22C Capital Investors
- 24Haymarket Investors
- 280 Capital Partners Investors
- 2bpartner Investors
- 2M Companies, Inc. Investors
- 2nd Generation Capital, LLC Investors
- 2x Consumer Products Growth Partners Investors
- 3 Rivers Capital Investors
- 32 Degrees Capital Investors
- 360° Capital Partners Investors
- 3d investors Investors
- 3E Bioventures Capital Investors
- 3G Capital Investors
- 3i Asia Ltd. Investors
- 3i Corporation Investors
- 3i Deutschland GmbH Investors
- 3i Europe plc Benelux Investors
- 3i Gestion S.A. Investors
- 3i Group plc Investors
- 3i India Pvt Ltd. Investors
- 3i Infrastructure plc Investors
- 3L Capital Investors
- 3P Equity Partners LLC Investors
- 3TS Capital Partners Investors
- 3W Partners Investors
- 406 Ventures, LLC Investors
- 42 Ventures, LLC Investors
- 424 Capital Investors
- 42CAP Manager GmbH Investors
- 4490 Ventures Investors
- 4BIO Capital Partners Investors
- 4C Capital LLC Investors
- 4D Global Energy Advisors Investors